Claims
- 1. A method for treating tumors comprising administering to a host a therapeutically effective dose of a composition comprising a platelet-derived growth factor (PDGF) aptamer and a cytotoxic agent.
- 2. The method of claim 1 wherein said PDGF aptamer is identified according to a method comprising:
a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with PDGF, wherein nucleic acids having an increased affinity to PDGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PDGF, whereby a nucleic acid ligand of PDGF may be identified.
- 3. The method of claim 1 wherein said PDGF aptamer is SEQ ID NO:1.
- 4. The method of claim 1 wherein said cytotoxic agent is selected from the group consisting of Bleomycin, Cisplatin, and Pt analogues; Carboplatin and Iproplatin, Cyclophosphamide, Daunorubicin, Doxofluoridine, Doxorubicin, Etoposide, Epirubicin, 5-Flurouracil, Gemzar, Ifosfamide, Melphalan, Methotrexate, Mithramycin, Mitomycin C, Mitoxanthrone, Streptozotocin, Taxol and Taxotere, Vincristine, Vinblastine, Vindesine, Vinorelbine, Topotecan and CPT-11.
- 5. A method for reducing the interstitial fluid pressure (IFP) of a tumor comprising administering a PDGF aptamer.
- 6. The method of claim 5 wherein said PDGF aptamer is identified according to a method comprising:
a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with PDGF, wherein nucleic acids having an increased affinity to PDGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PDGF, whereby a nucleic acid ligand of PDGF may be identified.
- 7. The method of claim 5 wherein said PDGF aptamer is SEQ ID NO:1.
- 8. A method for increasing the uptake of cytotoxic agents into a tumor comprising administering to a host a composition comprising a PDGF aptamer and a cytotoxic agent.
- 9. The method of claim 8 wherein said PDGF aptamer is identified according to a method comprising:
a) preparing a candidate mixture of nucleic acids; b) contacting the candidate mixture of nucleic acids with PDGF, wherein nucleic acids having an increased affinity to PDGF relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to PDGF, whereby a nucleic acid ligand of PDGF may be identified.
- 10. The method of claim 8 wherein said PDGF aptamer is SEQ ID NO:1.
- 11. The method of claim 8 wherein said cytotoxic agent is selected from the group consisting of Bleomycin, Cisplatin, and Pt analogues; Carboplatin and Iproplatin, Cyclophosphamide, Daunorubicin, Doxofluoridine, Doxorubicin, Etoposide, Epirubicin, 5-Flurouracil, Gemzar, Ifosfamide, Melphalan, Methotrexate, Mithramycin, Mitomycin C, Mitoxanthrone, Streptozotocin, Taxol and Taxotere, Vincristine, Vinblastine, Vindesine, Vinorelbine, Topotecan and CPT-11.
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60/205,006, filed May 17, 2000. This application is also a continuation in part of U.S. Pat. No. 5,674,685, issued Oct. 7, 1997, U.S. Pat. No. 5,668,264, issued Sep. 16, 1997 and U.S. Pat. No. 5,723,594, issued Mar. 3, 1998, each entitled “High Affinity PDGF Nucleic Acid Ligands,” and U.S. Pat. No. 6,229,002, issued, May 8, 2001, entitled “Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes.”
Provisional Applications (1)
|
Number |
Date |
Country |
|
60205006 |
May 2000 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
08479725 |
Jun 1995 |
US |
Child |
09859724 |
May 2001 |
US |
Parent |
08479783 |
Jun 1995 |
US |
Child |
09859724 |
May 2001 |
US |
Parent |
08618693 |
Mar 1996 |
US |
Child |
09859724 |
May 2001 |
US |
Parent |
08991743 |
Dec 1997 |
US |
Child |
09859724 |
May 2001 |
US |